A5063093037- Colorectal Cancer Treatments and Studies
- Lung Cancer Treatments and Mutations
- Gastric Cancer Management and Outcomes
- Lung Cancer Research Studies
- Cancer Diagnosis and Treatment
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers
- Cancer Treatment and Pharmacology
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Genomics and Diagnostics
- Radiomics and Machine Learning in Medical Imaging
- Advanced Breast Cancer Therapies
- Chronic Lymphocytic Leukemia Research
- Genetic factors in colorectal cancer
- Inflammatory Biomarkers in Disease Prognosis
- Cancer therapeutics and mechanisms
- Cancer, Lipids, and Metabolism
- Colorectal and Anal Carcinomas
- Cancer Risks and Factors
- Neuroendocrine Tumor Research Advances
- Multiple and Secondary Primary Cancers
- Colorectal Cancer Surgical Treatments
- Renal cell carcinoma treatment
- Breast Cancer Treatment Studies
- Gastrointestinal Tumor Research and Treatment
Necmettin Erbakan University
2016-2025
Antalya IVF
2024
Akdeniz University
2002-2023
Ankara University
2023
Dicle University
2023
Creative Commons
2023
Bridge University
2022
Afyon Kocatepe University
2022
University Research Co (United States)
2022
Konya Eğitim ve Araştırma Hastanesi
2022
There is no standard treatment recommended at category 1 level in international guidelines for subsequent therapy after cyclin-dependent kinase 4/6 inhibitor (CDK4/6) based therapy. We aimed to evaluate which oncologists prefer patients with disease progression under CDKi. In addition, we show the effectiveness of systemic treatments CDKi and whether there a survival difference between hormonal (monotherapy vs. mTOR-based).A total 609 from 53 centers were included study....
Central nervous system (CNS) metastases can be seen at a rate of 30% in advanced stages for patients with non-small cell lung cancer (NSCLC). Growing evidence indicates the predictive roles driver gene mutations development brain (BM) recent years, meaning that oncogene-driven NSCLC have high incidence BM diagnosis. Today, 3rd generation targeted drugs intracranial efficacy, which cross blood-brain barrier, made positive contribution to survival these an increased propensity BM. It is...
Background: Although higher-generation TKIs are associated with improved progression-free survival in advanced NSCLC patients EGFR mutations, the optimal selection of TKI treatment remains uncertain. To address this gap, we developed a web application powered by reinforcement learning (RL) algorithm to assist guiding initial decisions. Methods: Clinical and mutational data from were retrospectively collected 14 medical centers. Only complete sufficient follow-up included. Multiple supervised...
The cysteine-rich epidermal growth factor ligand domain 2 protein (CRELD2) is associated with pathways that regulate epithelial-to-mesenchymal transition, a critical process driving cancer metastasis. This study aimed to determine the prognostic value of CRELD2 status on survival outcomes in triple-negative breast (TNBC). Seventy patients were included study. Thirty-four metastatic, and 36 non-metastatic. expression tumor tissue was determined by immunohistochemical (IHC) staining. divided...
<title>Abstract</title> <bold>Aim:</bold> Immunotherapy has brought a new perspective to cancer treatments. However, the response of patients novel drug is heterogeneous. It essential reveal factors that may affect outcomes. was aimed evaluate effect antibiotherapy (Abx) on overall survival (OS) and progression-free (PFS) in with metastatic renal cell carcinoma (mRCC) receiving second-line nivolumab treatment. <bold>Method:</bold> The study multicentre, retrospective, multicentre design...
In the practice of oncology, effective communication between physician and patient is very important. Although many studies have indicated that a large majority physicians, especially from Western countries, tell truth about diagnosis prognosis, little known attitudes physicians in Turkey toward truth-telling.In this study, we tried to determine truth-telling explore potential related factors with self-reported questionnaire.Using questionnaire, 131 cancer specialists were interviewed during...
BackgroundIn the phase III OlympiAD trial, olaparib significantly increased progression-free survival (PFS) compared with chemotherapy of physician's choice in patients germline BRCA-mutated (gBRCAm), human epidermal growth factor 2 (HER2)-negative metastatic breast cancer (mBC). The IIIb LUCY trial assessed clinical effectiveness similar patients, a setting reflecting practice.MethodsThis open-label, single-arm (300 mg, twice daily) enrolled BRCAm, HER2-negative mBC who had received taxane...
Aim: The development of new treatment strategies for cancer patients resulted in an increase patient visits to emergency departments (EDs). purpose this study is determine clinical characteristics, causes, and predictors short term prognosis admissions the ED. Materials Methods: This prospective, clinical, observational was carried out adult ED a tertiary hospital with annual census 55,000. All visiting within 6-month period were enrolled into followed up at 1st 3rd months afterwards....
This study aimed to determine the epidemiological characteristics of colorectal cancer in Turkey.In this multicenter, prospective, and cross-sectional registry study, data for 968 patients with from 21 centers 7 geographic regions were analyzed.Diagnosis was colon 662 (68.4%) rectum 306 (31.6%) patients. In total, 60.9% male; mean age 58.9±12.6 years. Among patients, 15.0% drinking alcohol, 17.5% smoking, 1.5% had familial history polyposis, diabetes mellitus, 1.0% inflammatory bowel...
40 Background: TNT has recently emerged as a standard treatment for LARC. However, use and outcome of the different regimens in real-world practice are largely unknown. Methods: This is an international, multicentre, retrospective study sponsored by Institut Jules Bordet, Brussels. Eligibility was limited to newly diagnosed LARC patients treated with between March 2013 May 2023 outside context clinical trial. The primary objective describe real-word across international centres. Secondary...
Abstract Background Pembrolizumab is a first-line therapy for certain patients with advanced/metastatic non-small cell lung cancer (NSCLC). Combining pembrolizumab other immunotherapies may enhance tumor killing and clinical outcomes. Epacadostat selective inhibitor of indoleamine 2,3-dioxygenase 1, an immuno-regulatory enzyme involved in tryptophan to kynurenine metabolism that inhibits T cell-mediated immune responses. Methods In this randomized phase II study, metastatic NSCLC expressing...
We aimed to form a risk prediction model assess the probability of intrahospital death in cancer patients at time hospitalisation. The medical records and relevant clinical parameters who died or were discharged from teaching hospital between 1997 2000 (n = 334) reviewed explore determinants death, which later verified prospectively 131). Eastern Cooperative Oncology Group (ECOG) performance status four, short duration disease (on logarithmic scale), emergency admission, low haemoglobin (Hb)...